Ozanimod
bms
['bms', 'bmsnews', 'bristol']
#media: at #acg2022, we re sharing phase 3 results on the duration of response to an oral treatment for #ulcerativecolitis. 
Patients are our purpose. We come together each day to discover, develop and deliver transformative science to help patients prevail over serious diseases.